Simvastatin
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Using the report template as specified (no additional skill applies — this is a direct content-generation task per the given Evidence Pack format).
Simvastatin: From Hypercholesterolemia to Familial Hypercholesterolemia
One-Sentence Summary
Simvastatin is an HMG-CoA reductase inhibitor (statin) originally used to lower LDL cholesterol in general hypercholesterolemia and mixed dyslipidemia. The TxGNN model predicts it may also be effective for Familial Hypercholesterolemia (FH), with 18 clinical trials and 18 publications currently supporting this direction — though the drug does not appear as a stand‑alone authorized product in this Evidence Pack’s EU registry.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypercholesterolemia / mixed dyslipidemia (general statin indication; no EU marketing authorization record found in this Evidence Pack) |
| Predicted New Indication | Familial Hypercholesterolemia |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L1 |
| EU Market Status | Not Marketed (0 authorizations on file) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, Simvastatin is a member of the statin (HMG-CoA reductase inhibitor) class. It inhibits the rate-limiting enzyme in hepatic cholesterol biosynthesis, which upregulates LDL receptor expression on hepatocytes and accelerates clearance of LDL cholesterol from the circulation. Its efficacy in reducing LDL-C in general hypercholesterolemia is well established.
Familial hypercholesterolemia is a genetic disorder in which reduced or dysfunctional LDL receptors lead to markedly elevated LDL-C from birth. Because statins act by upregulating the remaining functional LDL receptors, they remain pharmacologically relevant even in heterozygous FH, where receptor function is only partially impaired — this is why simvastatin (and other statins) appear repeatedly as background/backbone therapy in nearly every major FH trial identified in the evidence, including trials of add-on agents such as ezetimibe (ENHANCE trial) and alirocumab (PCSK9 inhibitor programs).
In effect, the TxGNN prediction reflects a mechanistic relationship that is already reflected in real-world clinical practice: statins including simvastatin are long-standing first-line/background therapy for FH, even though this Evidence Pack does not show a corresponding formal EU marketing authorization or local labeling data for that specific indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03884452 | Phase 3 | Completed | 50 | Ezetimibe 10mg added to atorvastatin or simvastatin in homozygous FH (HoFH) |
| NCT00552097 | Phase 3 | Completed | 720 | ENHANCE trial: ezetimibe + high-dose simvastatin vs simvastatin alone on carotid atherosclerosis progression in heterozygous FH |
| NCT00129402 | Phase 3 | Completed | 248 | Ezetimibe + simvastatin vs simvastatin alone in adolescents with heterozygous FH |
| NCT03885921 | Phase 3 | Completed | 44 | Long-term (24-month) safety/tolerability of ezetimibe added to atorvastatin or simvastatin in HoFH |
| NCT00654446 | Phase 3 | Completed | 442 | Renal effects of rosuvastatin vs simvastatin in Fredrickson Type IIa/IIb dyslipidemia incl. heterozygous FH |
| NCT00465088 | Phase 3 | Completed | 199 | SUPREME study: niacin ER + simvastatin vs atorvastatin on HDL-C in hyperlipidemia/mixed dyslipidemia |
| NCT00145574 | Phase 4 | Completed | 194 | Colesevelam added to stable statin (including simvastatin) in pediatric heterozygous FH |
| NCT02107898 | Phase 3 | Completed | 216 | Alirocumab add-on to stable statin therapy in heterozygous FH / high CV risk hypercholesterolemia |
| NCT01709500 | Phase 3 | Completed | 249 | Alirocumab add-on to lipid-modifying therapy (incl. statins) in heterozygous FH |
| NCT03510884 | Phase 3 | Completed | 153 | Alirocumab in children/adolescents with heterozygous FH on optimal statin therapy |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18376000 | 2008 | RCT | New England Journal of Medicine | ENHANCE trial: simvastatin ± ezetimibe on atherosclerosis progression in heterozygous FH |
| 31696945 | 2019 | Cochrane Review | Cochrane Database of Systematic Reviews | Systematic review of statin therapy (including simvastatin) in children with FH |
| 15794711 | 2005 | Review | Expert Opinion on Drug Safety | Benefits and risks of simvastatin specifically in familial hypercholesterolaemia |
| 12908847 | 2003 | Review | Drug Safety | Long-term safety/tolerability considerations for simvastatin in FH |
| 2083515 | 1990 | Review | Drugs | Pharmacological properties and therapeutic potential of simvastatin in hypercholesterolaemia |
| 15554726 | 2004 | Review | American Journal of Cardiovascular Drugs | Ezetimibe/simvastatin combination in management of hypercholesterolemia |
| 27417002 | 2016 | Observational Study | Journal of the American College of Cardiology | Statin therapy (incl. simvastatin) reduces coronary artery disease events and mortality in heterozygous FH |
| 28437620 | 2017 | Guideline | Endocrine Practice | AACE/ACE guidelines for dyslipidemia management, referencing statin use in FH |
| 35629051 | 2022 | Observational Study | Journal of Clinical Medicine | Cellular immunity parameters in children with FH treated with simvastatin |
| 32800790 | 2020 | Case Report | Journal of Clinical Lipidology | Long-term pharmacological management of a pediatric severe compound heterozygous FH case |
EU Market Information
No EU marketing authorizations are recorded for Simvastatin in this Evidence Pack (0 authorizations, market status: Not Marketed). This should be verified independently before proceeding, as it is inconsistent with simvastatin’s broadly known status as a long-marketed generic statin in the EU — the discrepancy itself is a data-quality flag for this candidate record.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Regulatory/safety data required for the S1 safety pre-assessment (TFDA-equivalent labeling warnings and contraindications) is a Blocking data gap, and the Evidence Pack shows no EU marketing authorization on file for this drug — both must be resolved before this candidate can advance, despite reasonably strong (L1) clinical trial and literature support for statin background therapy in familial hypercholesterolemia.
To proceed, the following is needed:
- Official product label / SmPC warnings and contraindications (resolve DG001)
- Detailed mechanism of action documentation from DrugBank (resolve DG002)
- Verification of actual EU marketing authorization status for simvastatin (current “0 licenses / Not Marketed” record appears inconsistent with known market reality and should be re-checked against source data)
- Formal DDI review, particularly given literature signals of clinically significant interactions (e.g., CYP3A4-mediated interactions with antiretroviral protease inhibitors, rhabdomyolysis risk)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.